| __timestamp | AstraZeneca PLC | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5842000000 | 22732000 |
| Thursday, January 1, 2015 | 4646000000 | 29245000 |
| Friday, January 1, 2016 | 4126000000 | 33206000 |
| Sunday, January 1, 2017 | 4318000000 | 31152000 |
| Monday, January 1, 2018 | 4936000000 | 10136000 |
| Tuesday, January 1, 2019 | 4921000000 | 45546000 |
| Wednesday, January 1, 2020 | 5299000000 | 43367000 |
| Friday, January 1, 2021 | 12437000000 | 81413000 |
| Saturday, January 1, 2022 | 12391000000 | 139304000 |
| Sunday, January 1, 2023 | 8040000000 | 192361000 |
| Monday, January 1, 2024 | 10207000000 | 159417000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, cost efficiency is a critical metric for success. Over the past decade, AstraZeneca PLC and Halozyme Therapeutics, Inc. have showcased contrasting trajectories in their cost of revenue. AstraZeneca, a global biopharmaceutical giant, has seen its cost of revenue fluctuate, peaking in 2021 with a staggering 124% increase from 2016. In contrast, Halozyme, a smaller biotech firm, has maintained a more modest cost structure, with its highest cost of revenue in 2023 being just 15% of AstraZeneca's 2021 peak.
This comparison highlights the scale and operational differences between large and small pharmaceutical companies. While AstraZeneca's expansive operations lead to higher costs, Halozyme's leaner model allows for more controlled spending. As the industry continues to innovate, understanding these dynamics is crucial for investors and stakeholders alike.
Cost Insights: Breaking Down AstraZeneca PLC and Bristol-Myers Squibb Company's Expenses
Cost of Revenue Comparison: AstraZeneca PLC vs GSK plc
Cost Insights: Breaking Down AstraZeneca PLC and Xenon Pharmaceuticals Inc.'s Expenses
Analyzing Cost of Revenue: AstraZeneca PLC and Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for AstraZeneca PLC and Travere Therapeutics, Inc.
Cost Insights: Breaking Down AstraZeneca PLC and Evotec SE's Expenses
Cost Insights: Breaking Down AstraZeneca PLC and Xencor, Inc.'s Expenses
Cost Insights: Breaking Down BeiGene, Ltd. and Halozyme Therapeutics, Inc.'s Expenses
Cost of Revenue: Key Insights for Walgreens Boots Alliance, Inc. and Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. vs Ionis Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs Ligand Pharmaceuticals Incorporated
Halozyme Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored